TARRYTOWN, N.Y., April 29, 2020 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management
participation as follows:
- Bank of America Securities Virtual Health Care Conference at
8:20 a.m. ET on Tuesday, May 12,
2020
- RBC Capital Markets Virtual Global Healthcare Conference at
9:45 a.m. ET on Tuesday, May 19,
2020
- Bernstein's 36th Annual Strategic Decisions
Conference at 10:00 a.m. ET on
Wednesday, May 27, 2020
The sessions may be accessed from the "Investors &
Media" page of Regeneron's website at
http://investor.regeneron.com/events-and-presentations.
Replays of the webcasts will be archived on the Company's website
for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading
biotechnology company that invents life-transforming medicines for
people with serious diseases. Founded and led for over 30 years by
physician-scientists, our unique ability to repeatedly and
consistently translate science into medicine has led to seven
FDA-approved treatments and numerous product candidates in
development, all of which were homegrown in our laboratories. Our
medicines and pipeline are designed to help patients with eye
diseases, allergic and inflammatory diseases, cancer,
cardiovascular and metabolic diseases, infectious diseases, pain
and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our proprietary
VelociSuite® technologies, such as
VelocImmune®, which uses unique
genetically-humanized mice to produce optimized fully-human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center, which
is conducting one of the largest genetics sequencing efforts in the
world.
For additional information about the company, please visit
www.regeneron.com or follow @Regeneron on Twitter.
Contact Information:
Investor
Relations
Justin
Holko
914.847.7786
justin.holko@regeneron.com
View original
content:http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-investor-conference-presentations-301048767.html
SOURCE Regeneron Pharmaceuticals, Inc.